PRESS RELEASE Intel Reports Fourth-Quarter and Full-Year 2022 Financial Results :: Intel Corporation (INTC) January 28, 2023
PRESS RELEASE Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis January 28, 2023
PRESS RELEASE American Express Delivers on 2022 Growth Plan With Full-Year Revenue Growth of 25% and Earnings Per Share of $9.85 January 28, 2023
Intel Reports Fourth-Quarter and Full-Year 2022 Financial Results :: Intel Corporation (INTC) January 28, 2023
Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis January 28, 2023
American Express Delivers on 2022 Growth Plan With Full-Year Revenue Growth of 25% and Earnings Per Share of $9.85 January 28, 2023
